Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acrylfentanyl is a **highly potent synthetic opioid analgesic** and a structural **analogue of fentanyl**. It is classified as a novel psychoactive substance and has featured in the illicit drug market as a designer drug. Acrylfentanyl acts primarily as a **partial agonist of the mu-opioid receptor** and produces classical opioid effects such as **analgesia, euphoria, and potentially fatal respiratory depression**. Its potency is slightly higher than that of fentanyl itself (IC50 to displace naloxone is 1.4 nM versus 1.6 nM for fentanyl) and it is associated with a somewhat longer duration of action[4][1][5]. Acrylfentanyl has **no accepted medical use** and is a Schedule I controlled substance in the United States[3][4]. It has been linked to clusters of fatal overdoses and is encountered in powder form or in solution for illicit use[7][9]. Its mechanism of action—mu-opioid receptor agonism—places it alongside other opioid narcotics of high abuse potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acrylfentanyl.